Fibrinogen, a Promising Marker to Evaluate Severity and Prognosis of Acute Exacerbation of Chronic Obstructive Pulmonary Disease: A Retrospective Observational Study
Wei Sun,Zhixin Cao,Yingmin Ma,Jing Wang,Liming Zhang,Zujin Luo
DOI: https://doi.org/10.2147/COPD.S361929
2022-06-03
International Journal of COPD
Abstract:Wei Sun, 1 Zhixin Cao, 1 Yingmin Ma, 2 Jing Wang, 1 Liming Zhang, 1 Zujin Luo 1 1 Department of Respiratory and Critical Care Medicine, Beijing Chaoyang Hospital, Capital Medical University, Beijing, People's Republic of China; 2 Department of Respiratory and Critical Care Medicine, Beijing Youan Hospital, Capital Medical University, Beijing, People's Republic of China Correspondence: Zujin Luo, Department of Respiratory and Critical Care Medicine, Beijing Chaoyang Hospital, Capital Medical University, Beijing, People's Republic of China, Email Background: Fibrinogen is increasingly being studied as an inflammatory biomarker in chronic obstructive pulmonary disease (COPD), but there are limited data on the role of fibrinogen in assessing the severity of acute exacerbation of COPD (AECOPD). This study aimed to explore whether circulating fibrinogen could be used as a surrogate to measure the severity and predict the prognosis of AECOPD. Methods: A total of 535 AECOPD patients diagnosed at our center from January 2016 to June 2021 were retrospectively enrolled in this study. The electronic medical record of each patient was retrieved to collect data on baseline characteristics and laboratory parameters, as well as the use of noninvasive positive-pressure ventilation (NPPV) and prognosis. Multiple linear regression analysis was used to identify independent factors associated with circulating fibrinogen values. Receiver-operating characteristic curve and multivariate logistic regression analysis were applied to further verify the use of fibrinogen to predict NPPV failure. Results: Compared to patients with fibrinogen 4 g/L) tended to have elevated inflammatory response and higher incidence of DVT/PTE, emphysema, pneumonia, and atherosclerosis. In addition, fibrinogen levels in NPPV-failure patients were significantly higher than non-NPPV patients and NPPV-success ones. The presence of emphysema, pneumonia, and history of long-term oxygen therapy and higher CRP levels and leukocyte counts were independent risk factors associated with increased fibrinogen levels in AECOPD. Furthermore, our data indicated that fibrinogen could be considered as a reliable biomarker to predict NPPV failure (AUC, 0.899, 95% CI 0.846– 0.952), with an OR of 7.702 (95% CI 2.984– 19.875; P 3.55 g/L can independently predict NPPV failure. Keywords: COPD, noninvasive positive-pressure ventilation, acute exacerbation, fibrinogen, predictor Chronic obstructive pulmonary disease (COPD) is characterized by progressive airflow limitation that is not fully reversible. 1 It is associated with chronic inflammation, both locally and systemically, which increases further during acute exacerbations (AEs). 2 It has been known that some inflammatory biomarkers are associated with AE, 3 disease progression, and severity of airflow obstruction. 4–6 Identification of these biomarkers not only provides a method of predicting prognosis but also helps with better understanding of the pathogenesis of COPD. A key modulator of inflammation and fibrosis development, as well as tissue injury, 7 fibrinogenhas been approved by the US Food and Drug Administration as a COPD biomarker for severity assessment. 8 Higher baseline fibrinogen is associated with increasing incidence of COPD, COPD hospitalization, and all-cause mortality 9 and related to severity of COPD. 10 One study found that fibrinogen level was higher during AE of COPD (AECOPD) and returned to baseline 40 days after exacerbation. 11 Fifteen-year follow-up data from the CARDIA study of 2,132 individuals showed an association between higher fibrinogen and greater loss of forced expiratory volume in 1 second (FEV 1 ) and forced vital capacity (FVC), regardless of smoking status. 12 Other studies have suggested that increasing fibrinogen levels are associated with the occurrence of COPD complications. 13,14 However, there has been little research on the role of fibrinogen during AECOPD and its association with noninvasive positive-pressure ventilation (NPPV). Our study aimed to explore whether circulating fibrinogen could be used as a surrogate to measure the severity and predict the prognosis of AECOPD. A total of 535 patients diagnosed with AECOPD at Beijing Chao-Yang Hospital (west campus) from January 2016 to June 2021 were retrospectively enrolled in this study. The patient-selection process -Abstract Truncated-
respiratory system